Skip to main content

Table 1 Antibody titers in sera of mice immunized with various doses of FI-MCMV with or without adjuvant by i.p. injection and viral loads in mouse organs after lethal viral challenge a

From: An adjuvanted inactivated murine cytomegalovirus (MCMV) vaccine induces potent and long-term protective immunity against a lethal challenge with virulent MCMV

Immunogen

FI-MCMV

ELISA titer (2n) of IgG antibodyb

Spleen virus titers (log10PFU/ml)

Salivary gland virus titers (log10PFU/ml)

Dosage (μg)

Immunization once

Immunization twice

Adjuvant-free

0.25

3.33 ± 0.58

5.67 ± 0.52

5.16 ± 0.22

Not donef

+ Chitosan

 

5.83 ± 1.17c

9.83 ± 1.17c

5.12 ± 0.28e

Not done

+ Alum

 

6.67 ± 1.63c

11.17 ± 0.98c

5.06 ± 0.21e

Not done

+ MF59

 

7.50 ± 1.52c

12.83 ± 1.47c,d

4.06 ± 0.62c,d,e

4.76 ± 0.48

Adjuvant-free

1

5.33 ± 0.58

9.17 ± 0.98

5.03 ± 0.40e

Not done

+ Chitosan

 

6.67 ± 1.15

12.67 ± 1.03c

4.83 ± 0.12e

5.46 ± 0.57

+ Alum

 

7.83 ± 0.98c

14.00 ± 0.63c

4.31 ± 0.83e

5.12 ± 0.91

+ MF59

 

11.33 ± 0.82c,d

15.33 ± 1.03c,d

3.45 ± 0.56c,e

4.34 ± 0.42

Adjuvant-free

4

8.67 ± 0.82

11.67 ± 1.03

4.85 ± 0.21e

5.70 ± 0.38

+ Chitosan

 

10.50 ± 0.55c

14.83 ± 1.17c

3.95 ± 0.48c,e

4.57 ± 0.74c

+ Alum

 

11.00 ± 0.89c

15.17 ± 0.41c

3.61 ± 0.66c,e

4.10 ± 0.27c

+ MF59

 

12.17 ± 0.75c

17.00 ± 1.10c,d

2.08 ± 0.81c,d,e

2.31 ± 0.43c,d

Chitosan only

-

Undetected

Undetected

5.76 ± 0.29

Not done

Alum only

 

Undetected

Undetected

5.83 ± 0.38

Not done

MF59 only

 

Undetected

Undetected

5.74 ± 0.18

Not done

Mock

 

Undetected

Undetected

5.61 ± 0.36

Not done

PBS

 

-

-

5.94 ± 0.25

Not done

  1. aThe mice were immunized by i.p. injection twice (3 weeks apart) with various doses of vaccine (0.25, 1, or 4 μg) with or without adjuvant (MF59, alum, or chitosan). Serum samples from immunized mice were obtained 3 weeks after the first and second immunization, respectively. Mice were challenged with a lethal dose of SG-MCMV 3 weeks after the boost. Spleen virus titers 5 days later and salivary gland virus titers 3 weeks after the challenge were measured. Results are expressed as means ± standard deviation of tested mice in each group.
  2. bSerum samples were diluted by two-fold serial dilutions and “n” represents the dilution factor.
  3. cSignificant difference (p < 0.05), compared with the corresponding adjuvant-free subjects.
  4. dSignificant difference (p < 0.05), compared with the corresponding alum adjuvant subjects.
  5. eSignificant difference (p < 0.05), compared with control subjects.
  6. fViral titer measurement was not performed because of the mouse death before the day 21 post-infection.